Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

F. Tazza, C. Lapucci, M. Cellerino, G. Boffa, G. Novi, I. Poire, E. Mancuso, N. Bruschi, E. Sbragia, A. Laroni, E. Capello, M. Inglese

Research output: Contribution to journalArticlepeer-review


During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according to the national recommendations. Out of the 83 RRMS patients whose infusion was scheduled between March and December 2020, 56 patients experienced a delay in treatment based on MS severity and SARS-CoV2 infection risk profile. In most cases, the immunophenotype was performed monthly to guide re-infusions. Specifically, B CD19 + cells repopulation rate was monitored. Mean infusion delay was 103,1 [SD 40,6] days, and none of the patients presented relapses or active disease at MRI at the end of the observation period. Treatment naïve status and the interval between immunophenotyping and the last ocrelizumab infusion were predictors of earlier B CD19 + cells repopulation. Two patients contracted SARS-CoV2 with complete recovery. Definitive data about Sars-Cov2 vaccine efficacy in patients treated with ocrelizumab are still lacking. Our findings suggest that a personalized treatment with a delayed infusion schedule does not compromise ocrelizumab short-term efficacy and may help to lengthen the therapeutic window for an effective response to SARS-CoV2 vaccine.

Original languageEnglish
Article number117501
JournalJournal of the Neurological Sciences
Publication statusPublished - Aug 15 2021


  • COVID-19
  • Efficacy
  • Multiple sclerosis
  • Ocrelizumab
  • Safety
  • Treatment

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?'. Together they form a unique fingerprint.

Cite this